Literature Review to Understand the Burden and Current Non-surgical Management of Moderate–Severe Pain Associated with Knee Osteoarthritis

To conduct a literature review exploring the humanistic burden, costs, and guideline recommendations for non-surgical management of moderate–severe pain in knee osteoarthritis (KOA).

Published studies (2018–25 April 2023) assessing the burden of moderate–severe pain in KOA were identified by searching Medline, Embase, EconLit, and Cochrane database, supplemented with grey literature hand searches and reference list snowballing. Treatment guidelines were also identified for key countries.

This review included 106 publications and 37 treatment guidelines. Patients with moderate–severe pain were found to experience a low quality of life (QoL) and an impaired ability to perform daily tasks. The economic burden of KOA was substantial, including cost of medical visits, non-operative treatment (physical therapy and hyaluronic acid [HA] being key drivers) and productivity losses. Non-steroidal anti-inflammatory drugs (NSAIDs) were among the most frequently used pharmacological treatments, with intra-articular (IA) injections used to varying degrees. Opioid use was also frequently reported. Guidelines universally recommended NSAIDs, albeit with limited dose and duration for oral NSAIDs. IA-corticosteroids were conditionally/moderately recommended for short-term use by most guidelines, while IA-HA and opioids were rarely recommended. Guidelines are not specific to patients with moderate–severe pain and do not distinguish between different KOA phenotypes.

KOA with moderate–severe pain is associated with substantial humanistic and economic burden. Real-world data suggest that some treatments are regularly used at high cost regardless of the lack of evidence-based recommendations. There remains a need for new treatment options that successfully relieve pain, improve QoL and delay the need for surgery.

Graphical abstract available for this article.